The issue with mass-marketed compounded drugs like Wegovy extends beyond IP infringement. It attacks the fundamental "social contract" of biopharma: companies invest billions in R&D for a period of market exclusivity. Allowing compounded copies to bypass this system erodes the incentive for all future drug development.

Hims & Hers' persistence in selling high-margin compounded GLP-1s, even as shortages ease, is a strategic choice born of necessity. Switching to low-margin branded drugs ($10-15 profit per script) would collapse their business model, making the high-risk strategy a "financial Hail Mary."

The threat from compounding pharmacies goes beyond patent workarounds. By offering drugs like tirzepatide in custom formulations, they enable flexible microdosing that can reduce side effects and improve patient outcomes. This model of personalization directly challenges the standardized, one-size-fits-all approach of mass-produced pharmaceuticals.

The surge in use of compounded GLP-1s, costing about half the price of branded versions, demonstrates huge untapped demand. Patients are willing to accept manufacturing and safety risks for affordability, proving price is a major barrier to adoption.

The Myriad Genetics case made naturally occurring compounds unpatentable. This removed the financial incentive for pharmaceutical companies to spend hundreds of millions on FDA trials for peptides, which are naturally derived. Compounding pharmacies filled the void until a 2023 FDA ban pushed these promising compounds into a risky, unregulated gray market.

Despite claims of "American-made" peptides, the raw Active Pharmaceutical Ingredient (API) for compounds sold by compounding pharmacies and research sites is almost exclusively synthesized in China. Finishing, packaging, and quality control may occur domestically, but the core ingredient is imported.

The emergence of low-cost, compounded versions of GLP-1 drugs from telehealth companies like Hims is creating significant pricing pressure on market leaders Novo Nordisk and Eli Lilly. This dynamic has pushed the pharma giants toward direct-to-consumer models with lower prices to compete.

Unlike standard prescriptions, where doctors do not profit from a drug's sale, a different model exists for compounded medications. Some clinicians purchase peptides from a pharmacy at one price and then sell them to patients at a substantial markup, creating a direct financial incentive.

The debate over Thymosin alpha-1 highlights a key market failure. Because it's an existing molecule that is difficult to patent, major pharmaceutical companies lack the financial incentive to fund expensive US FDA trials. This creates a vacuum where a potentially effective drug is only accessible through unregulated channels.